cardiovascular disease
Heart disease drug development is falling
August 30, 2016Manufacturing and Production, Research and Development cardiovascular disease, heart disease, research and development
The number of drugs currently in development to combat heart disease has fallen in the last 20 years, it has …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
Google and AHA to fund $50m cardiovascular disease project
November 13, 2015Medical Communications, Research and Development American Heart Association, cardiovascular disease, google, heart disease
The American Heart Association and Google Life Sciences have announced a joint research collaboration to bring ‘unconventional thinking’ to the …
NICE issues draft guidance for MSD’s Ezetrol
October 21, 2015Sales and Marketing MSD, NICE, cardiovascular disease, ezetimibie, ezetrol, high cholesterol
NICE has published draft guidance recommending MSD’s Ezetrol as an option for some adults with high cholesterol. The guidance updates …
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
NHS looks to ESC for next-gen heart drug data
August 28, 2015Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent
New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
BMS enters gene therapy development deal
April 7, 2015Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure
Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …
Latest content
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
